학술논문
353TiP HER2CLIMB-02: A randomized, double-blind, phase III study of tucatinib or placebo with T-DM1 for unresectable locally advanced or metastatic HER2+ breast cancer
Document Type
Abstract
Author
Source
In Annals of Oncology September 2020 31 Supplement 4:S390-S390
Subject
Language
ISSN
0923-7534